河北常山生化药业股份有限公司 关于控股股东部分股票解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300255 证券简称：常山药业 公告编号：2025-25 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | 股东名称 | 持股数量 | 持股比例 | 累计质押 股份数量 | 占其所 持股份 | 占公司 总股本 | 已质押股份情况 已质押股 | | 未质押股份情况 | 占未质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 份限售和 | 占已质 | 未质押股 | | | | （股） | | （股） | 比例 | 比例 | 冻结、标 | 押股份 | 份限售和 | 押股份 | | | | | | | | 记数量 | 比例 | 冻结数量 | 比例 | | 高树华 | 280,644,728 | 30.54% | 149,342,900 | 53.21% | 16.25% | 0 | 0% | 0 | 0% | 注：上表"已 ...

Group 1: Product Development and Clinical Trials - The company has completed the production capacity for Aibennate, with an annual production capability of over 20 million units [2] - The clinical trial for CSCJC3456 is progressing normally, with ongoing Phase I trials [2][5] - Aibennate is currently in the CDE's professional review stage for market approval [4][6] Group 2: Financial Projections and Revenue - The company aims to achieve over 10 billion in sales during the 14th Five-Year Plan period, having completed approximately 7 billion in sales so far [6] - The revenue for the second quarter is uncertain, and the company has not disclosed specific revenue projections [5][6] - The pricing for Aibennate will be determined post-approval based on market competition and production costs [4][8] Group 3: Market Strategy and Competition - Aibennate is positioned as a new GLP-1 drug, facing competition from multiple existing products in the market [8] - The company has not planned to introduce strategic investors at this time [7] - The company is focusing on expanding its heparin export business, particularly in formulation exports [8] Group 4: Internal Control and Management - The company is continuously optimizing its internal control system to mitigate management risks [3] - There are no plans to divest the heparin business despite its recent lack of profitability [7]

Group 1 - The People's Bank of China emphasizes the implementation of a moderately loose monetary policy to meet the financing needs of the real economy and support key areas such as technological innovation and consumption [2] - The Ministry of Finance reports that from January to April, the national general public budget revenue reached 80,616 billion yuan, a year-on-year decrease of 0.4%, with the decline narrowing by 0.7 percentage points compared to the first quarter [3] - In April, tax revenue increased by 1.9% year-on-year, marking the first month of positive growth this year, while the total tax revenue from January to April was 65,556 billion yuan, down 2.1% year-on-year [4] Group 2 - The Ministry of Finance announces that the securities transaction stamp duty for January to April was 53.5 billion yuan, a year-on-year increase of 57.8% [5] - The National Energy Administration reports that the total electricity consumption in April was 7,721 billion kilowatt-hours, a year-on-year increase of 4.7% [6] - The National Development and Reform Commission states that most policies aimed at stabilizing employment and the economy are expected to be implemented by the end of June [8] Group 3 - The National Development and Reform Commission highlights the need to address "involution" competition that distorts market mechanisms and disrupts fair competition [9] - The China Automobile Industry Association reports that the top ten car manufacturers sold 2.502 million vehicles from January to April, accounting for 68.7% of total car sales [10] - A joint document from the Central Cyberspace Affairs Commission, the National Development and Reform Commission, and the Ministry of Industry and Information Technology outlines goals for IPv6 deployment by 2025, including reaching 850 million active users [11] Group 4 - Various companies are making significant moves, such as Zhaoyi Innovation planning to issue H-shares and list on the Hong Kong Stock Exchange, and several companies announcing share repurchase plans [13] - The Ministry of Finance reports that the total assets and loan growth rates of state-owned banks have slightly declined compared to 2024, but remain relatively high [14] - Zhongtai Securities discusses the logic behind the recent rise in bank stocks, indicating a strong rationale for continued investment in this sector [15]

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Group 1: Financial Support and Economic Policies - The People's Bank of China emphasizes the implementation of a moderately loose monetary policy to meet the financing needs of the real economy and maintain reasonable growth in financial totals [2] - The meeting highlighted the need to support key areas such as technological innovation, consumption, small and micro enterprises, and stabilizing foreign trade [2] - The National Development and Reform Commission plans to implement most employment and economic stabilization policies by the end of June [8] Group 2: Fiscal Revenue and Taxation - From January to April, the national general public budget revenue reached 80,616 billion yuan, a year-on-year decrease of 0.4%, with the decline narrowing by 0.7 percentage points compared to the first quarter [3] - In April, tax revenue increased by 1.9% year-on-year, marking the first month of positive growth this year [4] - The securities transaction stamp duty for January to April was 53.5 billion yuan, a year-on-year increase of 57.8% [5] Group 3: Energy Consumption - In April, the total electricity consumption reached 7,721 billion kilowatt-hours, a year-on-year increase of 4.7% [6] - From January to April, total electricity consumption was 31,566 billion kilowatt-hours, with a year-on-year growth of 3.1% [6] Group 4: Automotive Industry - In the first four months, the top ten car manufacturers sold 2.502 million vehicles, accounting for 68.7% of total car sales [11] - Among these manufacturers, BYD, Geely, SAIC-GM-Wuling, and FAW saw varying degrees of sales growth compared to the same period last year [11] Group 5: IPv6 Deployment - The Central Cyberspace Affairs Commission, National Development and Reform Commission, and Ministry of Industry and Information Technology aim to establish a leading global IPv6 technology and application system by the end of 2025 [12] - The target includes reaching 850 million active IPv6 users and 1.1 billion IoT IPv6 connections [12]

Group 1 - Hongjing Technology signed a service contract for an intelligent computing project with a total amount of 597 million yuan, valid for 5 years [1] - Weifu High-Tech's subsidiary invested 220 million yuan to establish a joint venture with Shanghai Baolong Automotive Technology [2] - Zhongshan Public received approval for the registration of short-term financing bonds amounting to 2 billion yuan and medium-term notes of 3 billion yuan [3] Group 2 - Lianhua Technology established a venture capital fund with a total commitment of 200 million yuan, contributing 100 million yuan as a limited partner [4] - Changan Technology's shareholder signed an agreement to transfer 6.27% of the company's shares to Hefei State Capital Venture Investment [6] - Hangzhou Garden announced a cash dividend of 0.5 yuan per 10 shares, totaling 6.62 million yuan [8] Group 3 - Huamao Technology plans to acquire 100% equity of Fuchuang Youyue, leading to a temporary suspension of its stock [9] - Zhuojin Co. won a bid for a soil remediation project in Hefei with a contract value of 67.68 million yuan [10] - Shanghai Pharmaceuticals received FDA approval for two drugs, enhancing its product portfolio [10] Group 4 - Fuxing Pharmaceutical's senior vice president resigned for personal reasons [12] - Baolong Technology's subsidiary plans to invest 180 million yuan in a joint venture [13] - ST Zhongdi intends to utilize surplus funds from a project company, with a maximum of 106 million yuan [14] Group 5 - Nanchao Food reported a significant decline in net profit for April, down 82.14% year-on-year [16] - Changshan Pharmaceutical received a drug registration certificate in Belarus for a new product [18] - Nanshan Aluminum established a wholly-owned subsidiary for photovoltaic energy projects with an investment of 5 million yuan [20] Group 6 - Bozhong Precision announced the resignation of a director and deputy general manager [22] - Xinjiang Jiaojian won a bid for a highway construction project valued at 451 million yuan [23] - Guangzhou Restaurant declared a cash dividend of 0.48 yuan per share, totaling 273 million yuan [25] Group 7 - Weili Medical's subsidiary obtained a medical device operating license, allowing it to engage in wholesale activities [27] - New Australia Co. announced a cash dividend of 0.3 yuan per share, totaling 219 million yuan [28] - Lianhua Technology's subsidiary entered the new third board innovation layer [29] Group 8 - Huaxi Energy's chairman resigned due to personal reasons [31] - Yipin Hong plans to use up to 500 million yuan of idle funds for cash management [33] - Shouhua Gas intends to purchase bauxite resources through market means [34] Group 9 - Jincheng signed a service agreement for underground mining operations at the Komakau Copper Mine, valued at approximately 805 million USD [34] - Wanrun New Energy signed a supply contract with CATL for lithium iron phosphate products, with a total supply of about 1.32 million tons [35] - Weili plans to transfer 100% equity of a subsidiary to Chengfa Environment for 100 million yuan [36] Group 10 - Zhenlei Technology's subsidiary received government subsidies of 2.21 million yuan, positively impacting profits [38] - Weir shares plan to change their name to "Haowei Group" to reflect strategic direction [39] - YTO Express reported a revenue increase of 16.32% in April, totaling 5.755 billion yuan [39]

河北常山生化药业股份有限公司（以下简称"公司"）于近日收到通知，公司药 品那屈肝素钙注射液获得白俄罗斯药品管理部门签发的药品注册证书，现将相关 情况公告如下： 一、药品注册文件的基本情况 药品名称：那屈肝素钙注射液 剂型：注射剂 证券代码：300255 证券简称：常山药业 公告编号：2025-24 河北常山生化药业股份有限公司 关于那屈肝素钙注射液获得白俄罗斯药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 规格：0.4ml、0.6ml 三、对公司的影响及风险提示 本次那屈肝素钙注射液获得白俄罗斯注册批文，对公司拓展海外市场带来一 定积极影响。目前公司肝素制剂产品海外销售收入占公司营业总收入比例较低。 药品销售容易受到海外市场政策环境变化、汇率波动、市场竞争等因素的影 响，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 河北常山生化药业股份有限公司董事会 2025 年 5 月 20 日 有效期至：2030 年 3 月 13 日 二、药品的其他相关情况 那屈肝素钙注射液主要用于治疗静脉血栓形成中度或高度危险的情况，预防 静脉血栓栓塞性疾 ...

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its product, Nadroparin Calcium Injection, from the Belarusian drug regulatory authority, valid until March 13, 2030. This approval is expected to positively impact the company's expansion into overseas markets [1]. Group 1 - The drug Nadroparin Calcium Injection is primarily used for the treatment of moderate to high-risk venous thromboembolism and the prevention of venous thromboembolic diseases [1]. - The registration approval in Belarus represents a significant step for the company in terms of international market penetration [1].

证券代码：300255 证券简称：常山药业 公告编号：2025-23 河北常山生化药业股份有限公司 关于举行 2024 年度业绩网上说明会的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 （问题征集专题页面二维码） 特此公告。 河北常山生化药业股份有限公司董事会 2025 年 5 月 19 日 河北常山生化药业股份有限公司（以下简称"公司"）2024 年年度报告全文 及摘要已于 2025 年 4 月 29 日刊登于巨潮资讯网 http://www.cninfo.com.cn。 为使投资者能够进一步了解公司的生产经营等情况，公司定于 2025 年 5 月 23 日（星期五）15:00－17:00 在全景网举办 2024 年度业绩网上说明会，本次年 度业绩说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://rs.p5w.net）参与互动交流。 出席本次说明会的人员有：公司董事长高晓东先生、财务总监岳晓华女士、 董事会秘书刘中英先生、独立董事曹德英先生。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度业绩网 ...

深圳市福田区中心五路 18 号星河中心大厦 19 层 电话：0755-23993388 传真：0755-86186205 邮编：518048 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 内容及该等议案所表述的事实或数据的真实性、准确性和完整性发表意见； 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东 资格、网络投票结果均由深圳证券交易所交易系统和互联网投票系统予以认证； 北京国枫（深圳）律师事务所 关于河北常山生化药业股份有限公司 2024 年度股东大会的 法律意见书 国枫律股字[2025]C0040 号 致：河北常山生化药业股份有限公司（贵公司） 北京国枫（深圳）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2024 年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以下 简称《证券法》）、《上市公司股东会规则》（以下简称《股东会规则》）、《律师事 务所从事证券法律业务管理办法》（以下简称《证券法律业务管理办法》 ...